Structural Basis for LFA-1 Inhibition upon Lovastatin Binding to the CD11a I-Domain

Author: Kallen J.   Welzenbach K.   Ramage P.   Geyl D.   Kriwacki R.   Legge G.   Cottens S.   Weitz-Schmidt G.   Hommel U.  

Publisher: Academic Press

ISSN: 0022-2836

Source: Journal of Molecular Biology, Vol.292, Iss.1, 1999-09, pp. : 1-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The lymphocyte function-associated antigen (LFA-1) belongs to the family of &bgr;2-integrins and plays an important role in T-cell activation and leukocyte migration to sites of inflammation. We report here that lovastatin, a drug clinically used for lowering cholesterol levels, inhibits the interaction of human LFA-1 with its counter-receptor intercellular adhesion molecule-1. Using nuclear magnetic resonance spectroscopy and X-ray crystallography we show that the inhibitor binds to a highly conserved domain of the LFA-1 -chain called the I-domain. The first three-dimensional structure of an integrin inhibitor bound to its receptor reveals atomic details for a hitherto unknown mode of LFA-1 inhibition. It also sheds light into possible mechanisms of LFA-1 mediated signalling and will support the design of novel anti-adhesive and immunosuppressive drugs.

Related content